On 2 June, Bristol-Myers Squibb (BMS) and BioNTech announced a global agreement to co-develop and commercialise BioNTech's bispecific antibody (BsAb) candidate BNT327 (PM8002, acquired from China's Biotheus) for multiple solid tumours. BMS will pay BioNTech USD 1.5 billion upfront, with USD 2 billion in non-contingent payments by 2028, plus up to USD 7.6 billion in milestones. Costs and profits will be shared equally. BNT327, the leading PD-L1/VEGF BsAb in global development, is in Phase III trials for lung cancer and planned for triple-negative breast cancer (TNBC) by late 2025. BioNTech had previously acquired global rights (excluding Greater China) for USD 55 million upfront and over USD 1 billion in milestones before buying Biotheus for USD 950 million in 2024.